645 related articles for article (PubMed ID: 29945500)
21. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
22. In silico design of HDAC6 inhibitors with neuroprotective effects.
Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
J Biomol Struct Dyn; 2022; 40(24):14204-14222. PubMed ID: 34784487
[TBL] [Abstract][Full Text] [Related]
23. In Silico Study Probes Potential Inhibitors of Human Dihydrofolate Reductase for Cancer Therapeutics.
Rana RM; Rampogu S; Zeb A; Son M; Park C; Lee G; Yoon S; Baek A; Parameswaran S; Park SJ; Lee KW
J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30754680
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
[TBL] [Abstract][Full Text] [Related]
25. HDAC6 detector: online application for evaluating compounds as potential histone deacetylase 6 inhibitors.
Tinkov OV; Grigorev VY; Grigoreva LD; Osipov VN; Kolotaev AV; Khachatryan DS
SAR QSAR Environ Res; 2023; 34(8):619-637. PubMed ID: 37565331
[TBL] [Abstract][Full Text] [Related]
26. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
[TBL] [Abstract][Full Text] [Related]
27. A Computational Approach to Investigate the HDAC6 and HDAC10 Binding Propensity of Psidium guajava-derived Compounds as Potential Anticancer Agents.
Adewole KE; Ishola AA
Curr Drug Discov Technol; 2021; 18(3):423-436. PubMed ID: 32357815
[TBL] [Abstract][Full Text] [Related]
28. Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies.
Patel P; Patel VK; Singh A; Jawaid T; Kamal M; Rajak H
Curr Comput Aided Drug Des; 2019; 15(2):145-166. PubMed ID: 29732991
[TBL] [Abstract][Full Text] [Related]
29. Do biological activities of selective histone deacetylase 6 (HDAC6) inhibitors rely on the modification of cap group?
Liu X; Wang S; Shi X; Lu M; Wang C; Li X; Zhang Y; Jia Q; Liu H
J Mol Recognit; 2022 Dec; 35(12):e2988. PubMed ID: 36054561
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
[TBL] [Abstract][Full Text] [Related]
31. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
[TBL] [Abstract][Full Text] [Related]
32. Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors.
Kavitha R; Karunagaran S; Chandrabose SS; Lee KW; Meganathan C
Biosystems; 2015 Dec; 138():39-52. PubMed ID: 26521124
[TBL] [Abstract][Full Text] [Related]
33. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
34. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking.
Lee YH; Yi GS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336555
[TBL] [Abstract][Full Text] [Related]
35. 3D-QSAR, molecular dynamics simulations, and molecular docking studies on pyridoaminotropanes and tetrahydroquinazoline as mTOR inhibitors.
Chaube U; Bhatt H
Mol Divers; 2017 Aug; 21(3):741-759. PubMed ID: 28577112
[TBL] [Abstract][Full Text] [Related]
36. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
Vögerl K; Ong N; Senger J; Herp D; Schmidtkunz K; Marek M; Müller M; Bartel K; Shaik TB; Porter NJ; Robaa D; Christianson DW; Romier C; Sippl W; Jung M; Bracher F
J Med Chem; 2019 Feb; 62(3):1138-1166. PubMed ID: 30645113
[TBL] [Abstract][Full Text] [Related]
38. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
39. Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
Dawood M; Elbadawi M; Böckers M; Bringmann G; Efferth T
Biomed Pharmacother; 2020 Sep; 129():110454. PubMed ID: 32768947
[TBL] [Abstract][Full Text] [Related]
40. Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation.
Bao Y; Zhou L; Dai D; Zhu X; Hu Y; Qiu Y
J Recept Signal Transduct Res; 2018; 38(5-6):413-431. PubMed ID: 30822195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
